natgillin/translations-raw huggingface dataset:
- In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity. 
- in vitro: inhibicija proliferacije osteoblasta, izravno citostatsko i proapoptotsko djelovanje na tumorske stanice, sinergistički citostatski učinak s drugim antitumorskim lijekovima,
In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section “Posology” above and section 4.4). 
U bolesnika s blagim do umjerenim oštećenjem funkcije bubrega preporučuju se snižene doze zoledronatne kiseline (vidjeti dio „Doziranje” iznad i dio 4.4).
Risk reduction of suffering from multiple events** 
p-vrijednost Stopa koštanog pobola p-vrijednost Smanjenje rizika od višestrukih događaja** (%)
Patients being treated with Zoledronic acid Actavis should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown. 
Actavis ne smiju istodobno uzimati takve lijekove ili bilo koji drugi bisfosfonat, budući da kombinirani učinci tih tvari nisu poznati.
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. 
Čimbenici koji mogu povećati mogućnost propadanja funkcije bubrega uključuju dehidraciju, postojeće oštećenje funkcije bubrega, višestruke cikluse primanja zoledronatne kiseline ili drugih bisfosfonata, kao i istodobnu primjenu nefrotoksičnih lijekova ili kraće trajanje infuzije od trenutno preporučenog.
Concentrate for solution for infusion 1 x 5 ml vial 
Koncentrat za otopinu za infuziju 1 x 5 ml bočica
In patients who show evidence of renal deterioration during treatment, Zoledronic acid Actavis should be withheld. 
U bolesnika u kojih se pojave znakovi pogoršanja funkcije bubrega tijekom liječenja treba prekinuti primjenu Zoledronatne kiseline Actavis.
Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Zoledronic acid Actavis outweighs the possible risk. 
Insuficijencija bubrega Bolesnike s hiperkalcemijom izazvanom tumorom i dokazanim pogoršanjem funkcije bubrega treba procijeniti na odgovarajući način i pritom razmotriti jesu li moguće koristi od liječenja Zoledronatnom kiselinom Actavis veće od mogućih rizika.
- The active substance is zoledronic acid. 
- Djelatna tvar je zoledronatna kiselina.
Zoledronic acid Actavis should only be resumed when serum creatinine returns to within 10% of baseline. 
S primjenom Zoledronatne kiseline Actavis smije se nastaviti tek kad se kreatinin u serumu vrati na vrijednosti unutar 10% početne vrijednosti.
Patients should have their serum creatinine levels assessed prior to each dose of Zoledronic acid Actavis. 
Bolesnicima treba provjeriti razinu kreatinina u serumu prije svake primjene doze Zoledronatne kiseline Actavis.
The first randomised, double-blind, placebo-controlled study compared zoledronic acid 4 mg to placebo for the prevention of skeletal related events (SREs) in prostate cancer patients. 
Prvo randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje uspoređivalo je zoledronatnu kiselinu u dozi od 4 mg s placebom u sprječavanju koštanih događaja u bolesnika s rakom prostate.
In a third phase III randomised, double-blind trial, 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. 
U randomiziranom, dvostruko slijepom ispitivanju faze III uspoređivala su se 4 mg zoledronatne kiseline s pamidronatom u dozi od 90 mg svaka 3 do 4 tjedna u bolesnika s multiplim mijelomom ili rakom dojke i najmanje jednom koštanom lezijom.
The multiple event analysis revealed a significant risk reduction of 16% in patients treated with 4 mg zoledronic acid in comparison with patients receiving pamidronate. 
Analiza višestrukih događaja pokazala je značajno smanjenje rizika za 16% u bolesnika liječenih zoledronatnom kiselinom u dozi od 4 mg u usporedbi s bolesnicima koji su primali pamidronat.
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic acid Actavis. 
Tijekom liječenja Zoledronatnom kiselinom Actavis sve bolesnike se mora poticati da održavaju dobru oralnu higijenu, redovito odlaze na stomatološke kontrole i odmah prijave bilo koji oralni simptom kao što je pomičnost zuba, bol ili oticanje, ili ranice koje ne cijele ili iscjedak.
What Zoledronic acid Actavis looks like and contents of the pack 
Kako Zoledronatna kiselina Actavis izgleda i sadržaj pakiranja
- To prepare an infusion solution containing 4 mg Zoledronic acid Actavis, further dilute the Zoledronic acid Actavis concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. 
Da biste pripremili otopinu za infuziju koja sadrži 4 mg Zoledronatne kiseline Actavis, dodatno razrijedite koncentrat Zoledronatne kiseline Actavis (5,0 ml) sa 100 ml otopine za infuziju koja ne sadrži kalcij niti druge dvovalentne katione.
- The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line. 
- Otopina koja sadrži zoledronatnu kiselinu primjenjuje se kao jednokratna intravenska infuzija u trajanju od 15 minuta putem zasebne infuzijske linije.
Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and older people 
Sprječavanje koštanih događaja u bolesnika s uznapredovalom zloćudnom bolešću koja je zahvatila kosti Odrasli i starije osobe
The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 ± 33% of the creatinine clearance, which showed a mean of 84 ± 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. 
Bubrežni klirens zoledronatne kiseline korelirao je s klirensom kreatinina, s time da je bubrežni klirens predstavljao 75 ± 33% klirensa kreatinina, koji je prosječno iznosio 84 ± 29 ml/min (raspon od 22 do 143 ml/min) u 64 uključena onkološka bolesnika.
- Zoledronic acid Actavis is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line. 
- Zoledronatna kiselina Actavis daje se u venu kao infuzija (drip) u trajanju od najmanje 15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
The MAH shall ensure that a patient reminder card regarding osteonecrosis of the jaw is implemented. 
Nositelj odobrenja mora osigurati uvođenje kartice s podsjetnikom za bolesnika u svezi osteonekroze čeljusti.
The effects of intravenous zoledronic acid in the treatment of paediatric patients (age 1 to 17 years) with severe osteogenesis imperfecta (types I, III and IV) were compared to intravenous pamidronate in one international, multicentre, randomised, open-label study with 74 and 76 patients in each treatment group, respectively. 
do 17 godina) s teškim oblikom osteogenesis imperfecta (tipovi I, III i IV) uspoređeni su s učincima intravenski primijenjenog pamidronata u jednom međunarodnom, multicentričnom, randomiziranom ispitivanju otvorenog tipa u dvije terapijske skupine, jedne sa 74 i druge sa 76 bolesnika.
Dizziness, paraesthesia, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence 
Omaglica, parestezija, disgeuzija, hipoestezija, hiperestezija, tremor, somnolencija Konvulzije, hipoestezija i tetanija (uslijed hipokalcemije)
Patients treated with Zoledronic acid Actavis should be given the package leaflet and the patient reminder card. 
Bolesnicima koji se liječe Zoledronatnom kiselinom Actavis potrebno je dati Uputu o lijeku i karticu s podsjetnikom za bolesnika.
Other medicines and Zoledronic acid Actavis 
Drugi lijekovi i Zoledronatna kiselina Actavis
The results demonstrated that 4 mg zoledronic acid showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. 
Rezultati su pokazali podjednaku djelotvornost zoledronatne kiseline u dozi od 4 mg i 90 mg pamidronata u sprječavanju koštanih događaja.
Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. 
Mnogi od tih bolesnika primali su i kemoterapiju i kortikosteroide i imali su znakove lokalne infekcije uključujući osteomijelitis.Većina zabilježenih slučajeva odnosila se na onkološke bolesnike nakon vađenja zuba ili drugih stomatoloških operacija.
In a second study including solid tumours other than breast or prostate cancer, zoledronic acid 4 mg significantly reduced the proportion of patients with an SRE, delayed the median time to first SRE by > 2 months, and reduced the skeletal morbidity rate. 
U drugom ispitivanju u bolesnika sa solidnim tumorima, izuzev raka dojke i prostate, zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s koštanim događajima, produljila medijan vremena do prvog koštanog događaja za više od 2 mjeseca i smanjila stopu koštanog pobola.
Zoledronic acid Actavis treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. 
Liječenje Zoledronatnom kiselinom Actavis u bolesnika s hiperkalcemijom izazvanom tumorom koji imaju i teško oštećenje funkcije bubrega dolazi u obzir tek nakon procjene rizika i koristi od liječenja.
The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. 
Izvučena količina koncentrata mora se dodatno razrijediti u 100 ml sterilne 0,9%-tne m/V otopine natrijevog klorida ili 5%-tne m/V otopine glukoze.
In the clinical trials, renal deterioration was defined as follows: - For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 micromol/l), an increase of 0.5 mg/dl or 44 micromol/l; - For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 micromol/l), an increase of 
- povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 mikromola/l, u bolesnika s normalnom početnom vrijednošću kreatinina u serumu (< 1,4 mg/dl ili < 124 mikromola/l); - povišenje vrijednosti kreatinina za 1,0 mg/dl ili 88 mikromola/l, u bolesnika s poremećenom početnom vrijednošću kreatinina (> 1,4 mg/dl ili > 124 mikromola/l).
Dyspnoea, cough, bronchoconstriction Interstitial lung disease 
Dispneja, kašalj, bronhokonstrikcija
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. 
koje napreduje do zatajenja bubrega i dijalize, zabilježeno je u bolesnika nakon početne doze ili jednokratne doze od 4 mg zoledronatne kiseline.
Zoledronic acid Actavis must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. 
Zoledronatnu kiselinu Actavis bolesnicima smiju propisivati i primjenjivati samo liječnici s iskustvom u intravenskoj primjeni bisfosfonata.
See section 4. 
DODATAK III.
To avoid potential incompatibilities, Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution. 
Kako bi se izbjegle moguće inkompatibilnosti, Zoledronatna kiselina Actavis 4 mg/5 ml koncentrat za otopinu za infuziju mora se razrijediti sa 0,9%-tnom m/V otopinom natrijevog klorida ili sa 5%-tnom m/V otopinom glukoze.
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko
Prior to administration, 5 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution). 
Prije primjene, 5 ml koncentrata iz jedne bočice ili izvučen potreban volumen koncentrata mora se dodatno razrijediti sa 100 ml otopine za infuziju koja ne sadrži kalcij (0,9%-tna m/V otopina natrijevog klorida ili 5%-tna m/V otopina glukoze).
Muscle spasms, osteonecrosis of the jaw Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction) and other anatomical sites including femur and hip 
Ostenekroza vanjskog slušnog kanala (nuspojava klase bifosfonatnih lijekova) i drugih anatomskih mjesta uključujući bedrenu kost i kuk
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4). 
Propadanje funkcije bubrega, koje napreduje do zatajenja bubrega i dijalize, zabilježeno je u bolesnika nakon početne doze ili jednokratne doze zoledronatne kiseline od 4 mg (vidjeti dio 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine < 400 micromol/l or < 4.5 mg/dl (see section 4.4). 
Nije potrebna prilagodba doze u bolesnika s hiperkalcemijom izazvanom tumorom i vrijednostima kreatinina u serumu < 400 mikromola/l ili < 4,5 mg/dl (vidjeti dio 4.4).
Zoledronic acid Actavis contains sodium 
Zoledronatna kiselina Actavis sadrži natrij
Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing) 
Vrućica, sindrom nalik gripi (uključujući umor, tresavicu, malaksalost i crvenilo uz osjećaj vrućine)
Your doctor will carry out blood tests before you start treatment with Zoledronic acid Actavis and will check your response to treatment at regular intervals. 
Prije nego što počnete primati Zoledronatnu kiselinu Actavis, liječnik će Vam napraviti krvne pretrage i u redovitim vremenskim razmacima provjeravati Vaš odgovor na liječenje.
After dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C and at 25°C after dilution in 100 ml 0.9% w/v sodium chloride solution or 100 ml 5% w/v glucose. 
Nakon razrjeđivanja: kemijska i fizikalna stabilnost nakon razrjeđenja u 100 ml 0,9%-tne m/V otopine natrijevog klorida ili 100 ml 5%-tne m/V otopine glukoze dokazana je za 24 sata na temperaturi od 2°C do 8°C i na 25°C.
Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post-marketing setting in patients receiving zoledronic acid. 
Osteonekroza čeljusti Osteonekroza čeljusti (ONČ) zabilježena je manje često u kliničkim ispitivanjima i nakon stavljanja u promet u bolesnika koji su se liječili zoledronatnom kiselinom.
- if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which Zoledronic acid Actavis belongs), or any of the other ingredients of this medicine (listed in section 6). 
Zoledronatna kiselina Actavis) ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
- The usual single dose given is 4 mg. - If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem. 
Ako imate tegobe s bubrezima, liječnik će Vam dati nižu dozu ovisno o težini tegoba koje imate s bubrezima.
Caution is advised when zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5). 
Savjetuje se oprez kod primjene zoledronatne kiseline s lijekovima za koje je poznato da uzrokuju hipokalcemiju budući da mogu imati sinergistički učinak s posljedičnom teškom hipokalcemijom
- History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures 
- Bolest zubiju u anamnezi, lošu oralnu higijenu, periodontalnu bolest, invazivne zahvate na zubima (npr. vađenje zuba) i zubnu protezu koja loše prijanja
Prevention of skeletal related events in patients with advanced malignancies involving bone: When initiating treatment with Zoledronic acid Actavis in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. 
Kad se počinje liječenje Zoledronatnom kiselinom Actavis u bolesnika s multiplim mijelomom ili solidnim tumorom s metastatskim lezijama kosti, potrebno je odrediti vrijednosti kreatinina u serumu i klirens kreatinina (CLcr).
The following conventional classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko
Zoledronic acid Actavis is supplied as a clear and colourless concentrate for solution for infusion (sterile concentrate) in a plastic vial. 
Zoledronatna kiselina Actavis isporučuje se kao bistri i bezbojni koncentrat za otopinu za infuziju
To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride or 5% w/v glucose solution. 
Da biste izbjegli moguće inkompatibilnosti, otopina za infuziju koja se koristi za razrjeđenje mora biti 0,9%-tna m/V otopina natrijevog klorida ili 5%
Zoledronic acid Actavis must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Zoledronatna kiselina Actavis ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Via Pasteur 10 
Actavis Italy S.p.A. Via Pasteur 10
In clinical studies, zoledronic acid, used as indicated in sections 4.1 and 4.2, has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring. 
4.2, primjenjivala istodobno s često davanim antitumorskim lijekovima, diureticima, antibioticima i analgeticima bez klinički vidljivih interakcija.
- Severe bone, joint and/or muscle pain, occasionally incapacitating. 
- Jaki, ponekad onesposobljavajući bolovi u kostima, zglobovima i/ili mišićima.
In the clinical studies, patients with serum creatinine > 400 micromol/l or > 4.5 mg/dl were excluded. 
Bolesnici s vrijednostima kreatinina u serumu > 400 mikromola/l ili > 4,5 mg/dl bili su isključeni iz kliničkih ispitivanja.
The frequencies for each of these identified risks are shown in Table 1. 
Učestalosti svakog pojedinog utvrđenog rizika navedene su u
Figure 1: Mean changes from baseline in BPI scores. 
Slika 1: Srednja vrijednost promjene rezultata na ljestvici bola (BPI) od početne vrijednosti.
Common (may affect up to 1 in 10 people): - Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests). 
- Teško oštećenje funkcije bubrega (obično će ga utvrditi liječnik pomoću određenih specifičnih krvnih pretraga).
10 x 5 ml vials 
10 x 5 ml bočica
This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Lijek se ne smije miješati s infuzijskim otopinama koje sadrže kalcij ili druge dvovalentne katione kao što je Ringerova otopina s laktatom i mora se primijeniti kao pojedinačna intravenska otopina putem odvojene infuzijske linije.
If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time. 
RMP-a, dokumenti mogu biti podneseni istodobno.
- Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs) - Flu-like symptoms including arthritis and joint swelling. 
- Intersticijska bolest pluća (upala tkiva oko vrećica zraka u plućima).
Package leaflet: Information for the user Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion zoledronic acid 
Uputa o lijeku: Informacije za korisnika Zoledronatna kiselina Actavis 4 mg/5 ml koncentrat za otopinu za infuziju zoledronatna kiselina
Median time to relapse (re-increase of albumin-corrected serum calcium ≥ 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid). 
Medijan vremena do relapsa (ponovnog povišenja kalcija u serumu korigiranog za albumin ≥ 2,9 mmol/l) iznosio je 30 do 40 dana u bolesnika liječenih zoledronatnom kiselinom za razliku od 17 dana u onih liječenih pamidronatom u dozi od
Do not mix Zoledronic acid Actavis concentrate with calcium-containing or other divalent cation containing solutions such as lactated Ringer's solution. 
Koncentrat Zoledronatne kiseline Actavis se ne smije miješati s otopinama koje sadrže kalcij ili druge dvovalentne katione kao što je Ringerova otopina s laktatom.
How often Zoledronic acid Actavis is given 
Koliko se često daje Zoledronatna kiselina Actavis
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture. 
kuku ili preponama, i svakog bolesnika s takvim simptomima treba pregledati na nepotpuni prijelom bedrene kosti.
Paediatric patients 
Posebne populacije Pedijatrijski bolesnici
4 x 5 ml vials 
4 x 5 ml bočice
In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid Actavis is used in combination with thalidomide. 
U bolesnika s multiplim mijelomom, rizik od poremećaja funkcije bubrega može biti povećan kad se
Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria Arthritis and joint swelling as a symptom of acute phase reaction 
Astenija, periferni edemi, reakcije na mjestu primjene injekcije (uključujući bol, nadraženost, oteklinu, otvrdnuće), bol u prsištu, povećanje tjelesne težine,
Uncommon (may affect up to 1 in 100 people): - Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. 
- Bol u ustima, zubima i/ili čeljusti, oteklina ili ranice u ustima ili čeljusti koje ne cijele, iscjedak, utrnulost ili osjećaj težine u čeljusti, klimanje zuba.
In clinical trials with zoledronic acid, patients with serum creatinine > 265 micromol/l or > 3.0 mg/dl were excluded. 
Bolesnici s vrijednošću kreatinina u serumu > 265 mikromola/l ili > 3,0 mg/dl bili su isključeni iz kliničkih ispitivanja sa zoledronatnom kiselinom.
4.1 ml for 3.3 mg dose 
4,4 ml za dozu od 3,5 mg 4,1 ml za dozu od 3,3 mg 3,8 ml za dozu od 3,0 mg
4.0 mg zoledronic acid 3.5 mg* zoledronic acid 3.3 mg* zoledronic acid 3.0 mg* zoledronic acid * Doses have been calculated assuming target AUC of 0.66 (mg•hr/l) (CLcr = 75 ml/min). 
4,0 mg zoledronatne kiseline 3,5 mg* zoledronatne kiseline 3,3 mg* zoledronatne kiseline 3,0 mg* zoledronatne kiseline